IM83 / Beijing Imunopharm - LARVOL DELTA

A milestone breakthrough in the treatment of osteosarcoma with IM83 CAR-T cells [Google translation] (bydrug.pharmcube.com) - "Recently, the Phase I clinical study of IM83 CAR-T cell therapy for relapsed or refractory osteosarcoma jointly conducted by Beijing Yimiao Shenzhou Pharmaceutical Technology Co., Ltd....and the Department of Orthopedic Oncology of Guangdong Provincial People's Hospital was officially launched, and the first patient has successfully completed treatment. This is not only the first clinical trial of CAR-T cell therapy for osteosarcoma in China, but also an important breakthrough in the field of immunotherapy for solid tumors worldwide."

Trial status • Osteosarcoma

IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

CAR T-Cell Therapy • New P1 trial • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

CAR T-Cell Therapy • Clinical • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • GPC3 • PD-1 • PD-L1

Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors (clinicaltrials.gov) - P1; N=10; Recruiting; Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

Clinical • New P1 trial • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • GPC3